Liver transplant with chemo-radiotherapy for unresectable hilar cholangiocarcinoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter study aims to evaluate the effectiveness of liver transplantation combined with neoadjuvant chemo-radiotherapy in patients diagnosed with unresectable hilar cholangiocarcinoma. Patients aged 70 or younger with tumors ≤3cm and no evidence of metastases will be included. The primary endpoint is overall survival at 1, 3, and 5 years post-transplant, while secondary endpoints include recurrence-free survival and the rate of patients who undergo transplantation. The study will involve comprehensive radiological evaluations to confirm eligibility.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Willing and able to provide written consent form
* Age ≤ 70 years-old
* ECOG 0 or 1
* Unresectable hCCA ≤3cm in radial diameter

Exclusion Criteria:

* Those patients who have received chemotherapy or radiotherapy previously out of protocol
* Liver, extrahepatic or lymph node metastases
* Previous intent of surgical resection or percutaneous biopsy
* Previous or concurrent cancer that is different in primary site or histology from adenocarcinoma, except cervical carcinoma in situ, localized prostate cancer, treated basal cell carcinoma, superficial bladder tumors (Ta, Tis, T1). Any cancer curatively treated 5 years prior to entry is permitted.
* Infection no controlled

Where it's running

• Department of HPB Surgery and Transplants, Hospital Vall d´Hebron
  Barcelona, Barcelona, Spain Recruiting

Study contacts

• Study coordinator: CRISTINA DOPAZO, MD/PhD
• Email: cristina.dopazo@vallhebron.cat
• Phone: +34932746113

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Alternating chemo-immunotherapy and FGFR inhibitor for FGFR-positive biliary tract cancer

  This phase 2 trial tests whether alternating gemcitabine/cisplatin with durvalumab and the FGFR2 inhibitor pemigatinib can help people with unresectable or metastatic biliary tract cancers that have FGFR alterations.

  Recruiting Phase 2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT07780838

• Combining radioembolization with immunotherapy for advanced bile duct cancer

  This study is testing a new treatment that combines a special type of radiation therapy with immunotherapy drugs to see if it can help patients with advanced bile duct cancer who can't have surgery.

  Recruiting Phase 1 Mayo Clinic · Jacksonville, Florida · NCT06058663

• Using modified immune cells and a vaccine to treat unresectable liver cancer after radiation therapy

  This study is testing a new way to treat liver cancer that can't be removed by surgery by using modified immune cells and a vaccine after radiation therapy to see if it helps patients feel better.

  Recruiting Phase 1/2 Mayo Clinic · Rochester, Minnesota · NCT03942328

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.